Stockhub

Seelos Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

18 August 2022

  • curprev 12:2812:28, 18 August 2022 >Paris 1,278 bytes +1,278 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the..."
Retrieved from "https://stockhub.co/research/Seelos_Therapeutics,_Inc."